Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein

Virology

Volumn 368, Issue 2, 2007, Pages 331-341

  Su, Hua Poo ^a   Golden, Joseph W ^b   Gittis, Apostolos G ^a   Hooper, Jay W ^b   Garboczi, David N ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Conformational epitope; Fab structure; Neutralizing antibody; Poxvirus L1R; Vaccinia

Indexed keywords

DNA VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10F5; MONOCLONAL ANTIBODY 7D11; NEUTRALIZING ANTIBODY; PROTEIN L1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISULFIDE BOND; MOLECULAR INTERACTION; NONHUMAN; OPEN READING FRAME; POXVIRUS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; CRYSTALLIZATION; DNA-BINDING PROTEINS; EPITOPES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; POXVIRIDAE; PROTEIN CONFORMATION; VACCINIA VIRUS; VERO CELLS; VIRAL CORE PROTEINS;

POXVIRIDAE; VARIOLA VIRUS;

EID: 35548999573     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.06.042     Document Type: Article

References (47)

1. Adams P.D., Pannu N.S., Read R., and Brunger A.T. Cross-validated maximum likelihood enhances crystallographic simulated annealing refinement. Proc. Natl. Acad. Sci. U.S.A. 94 10 (1997) 5018-5023
2. Aldaz-Carroll L., Whitbeck J., Ponce De Leon M., Lou H., Pannell L., Lebowitz J., Fogg C., White C.L., Moss B., Cohen G.H., and Eisenberg R. Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology 341 1 (2005) 59-71
3. Belongia E., and Naleway A. Smallpox vaccine: the good, the bad, and the ugly. Clin. Med. Res. 1 2 (2003) 87-92
4. Blouch R., Byrd C., and Hruby D. Importance of disulphide bonds for vaccinia virus L1R protein function. Virol. J. 2 (2005) 91
5. Chen Z., Earl P., Americo J., Damon I., Smith S.K., Zhou Y., Yu F., Sebrell A., Emerson S., Cohen G., Eisenberg R., Svitel J., Schuck P., Satterfield W., Moss B., and Purcell R. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc. Natl. Acad. Sci. U.S.A. 103 6 (2006) 1882-1887
6. Coulibaly S., Bruhl P., Mayrhofer J., Schmid K., Gerencer M., and Falkner F. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341 1 (2005) 91-101
7. Davies D.R., Padlan E., and Sheriff S. Antibody-antigen complexes. Annu. Rev. Biochem. 59 (1990) 439-473
8. Davies D., Mccausland M., Valdez C., Huynh D., Hernandez J., Mu Y., Hirst S., Villarreal L., Felgner P., and Crotty S. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J. Virol. 79 18 (2005) 11724-11733
9. DeLano, W., 2002. The PyMOL molecular graphics system (http://www.pymol.org).
10. Fogg C., Lustig S., Whitbeck J., Eisenberg R., Cohen G., and Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78 19 (2004) 10230-10237
11. Galmiche M., Goenaga J., Wittek R., and Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254 1 (1999) 71-80
12. Granata V., Housden N., Harrison S., Jolivet-Reynaud C., Gore M., and Stura E.A. Comparison of the crystallization and crystal packing of two Fab single-site mutant protein L complexes. Acta Crystallogr., D Biol. Crystallogr. 61 Pt. 6 (2005) 750-754
13. Harrison S., Alberts B., Ehrenfeld E., Enquist L., Fineberg H., Mcknight S., Moss B., O'donnell M., Ploegh H., Schmid S., Walter K., and Theriot J. Discovery of antivirals against smallpox. Proc. Natl. Acad. Sci. U.S.A. 101 31 (2004) 11178-11192
14. Henderson D., Inglesby T., Bartlett J., Ascher M.S., Eitzen E., Jahrling P., Hauer J., Layton M., Mcdade J., Osterholm M., O'toole T., Parker G., Perl T., Russell P., and Tonat K. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281 22 (1999) 2127-2137
15. Heraud J., Edghill-Smith Y., Ayala V., Kalisz I., Parrino J., Kalyanaraman V.S., Manischewitz J., King L., Hryniewicz A., Trindade C., Hassett M., Tsai W., Venzon D., Nalca A., Vaccari M., Silvera P., Bray M., Graham B., Golding H., Hooper J., and Franchini G. Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177 4 (2006) 2552-2564
16. Hooper J., Custer D.M., Schmaljohn C., and Schmaljohn A. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266 2 (2000) 329-339
17. Hooper, J., Schmaljohn, A., Schmaljohn, C., 2002. Prophylactic therapeutic monoclonal antibodies. United States of America.
18. Hooper J., Custer D., and Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306 1 (2003) 181-195
19. Hooper J.W., Thompson E., Wilhelmsen C., Zimmerman M., Ichou M., Steffen S.E., Schmaljohn C., Schmaljohn A., and Jahrling P. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78 9 (2004) 4433-4443
20. Hooper J., Golden J., Ferro A.M., and King A. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 25 10 (2007) 1814-1823
21. Ichihashi Y., and Oie M. Neutralizing epitope on penetration protein of vaccinia virus. Virology 220 2 (1996) 491-494
22. Ichihashi Y., Takahashi T., and Oie M. Identification of a vaccinia virus penetration protein. Virology 202 2 (1994) 834-843
23. Jones T., Zou J., Cowan S., and Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47 Pt. 2 (1991) 110-119
24. Kashmiri S., De Pascalis R., Gonzales N., and Schlom J. SDR grafting-A new approach to antibody humanization. Methods 36 1 (2005) 25-34
25. Kidokoro M., Tashiro M., and Shida H. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc. Natl. Acad. Sci. U.S.A. 102 11 (2005) 4152-4157
26. Lamarre A., and Talbot P. Protection from lethal coronavirus infection by immunoglobulin fragments. J. Immunol. 154 8 (1995) 3975-3984
27. Lawrence M., and Colman P. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234 4 (1993) 946-950
28. Lee B., and Richards F. The interpretation of protein structures: estimation of static accessibility. J. Mol. Biol. 55 3 (1971) 379-400
29. Lustig S., Fogg C., Whitbeck J., Eisenberg R., Cohen G.H., and Moss B. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J. Virol. 79 21 (2005) 13454-13462
30. McCoy A.J., Grosse-Kunstleve R.W., Storoni L., and Read R. Likelihood-enhanced fast translation functions. Acta Crystallogr., D Biol. Crystallogr. 61 Pt. 4 (2005) 458-464
31. Moss B. Poxvirus entry and membrane fusion. Virology 344 1 (2006) 48-54
32. Murshudov G., Vagin A., and Dodson E. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., D Biol. Crystallogr. 53 Pt. 3 (1997) 240-255
33. Neves-Petersen M.T., Snabe T., Klitgaard S., Duroux M., and Petersen S. Photonic activation of disulfide bridges achieves oriented protein immobilization on biosensor surfaces. Protein Sci. 15 2 (2006) 343-351
34. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. In: Carter C.W., and Sweet R.M. (Eds). Methods in Enzymology vol. 276 (1997), Academic Press 307-326
35. Padlan E., Abergel C., and Tipper J. Identification of specificity-determining residues in antibodies. FASEB J. 9 1 (1995) 133-139
36. Ravanello M., and Hruby D. Conditional lethal expression of the vaccinia virus L1R myristylated protein reveals a role in virion assembly. J. Virol. 68 10 (1994) 6401-6410
37. Ravanello M., Franke C.A., and Hruby D.E. An NH2-terminal peptide from the vaccinia virus L1R protein directs the myristylation and virion envelope localization of a heterologous fusion protein. J. Biol. Chem. 268 10 (1993) 7585-7593
38. Sakhatskyy P., Wang S., Chou T., and Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 355 2 (2006) 164-174
39. Schmaljohn C., Cui Y., Kerby S., Pennock D., and Spik K. Production and characterization of human monoclonal antibody Fab fragments to vaccinia virus from a phage-display combinatorial library. Virology 258 1 (1999) 189-200
40. Senkevich T., Ojeda S., Townsley A., Nelson G.E., and Moss B. Poxvirus multiprotein entry-fusion complex. Proc. Natl. Acad. Sci. U.S.A. 102 51 (2005) 18572-18577
41. Senkevich T., White C., Koonin E., and Moss B. Complete pathway for protein disulfide bond formation encoded by poxviruses. Proc. Natl. Acad. Sci. U.S.A. 99 10 (2002) 6667-6672
42. Su H., Garman S., Allison T.J., Fogg C., Moss B., and Garboczi D. The 1.51-Angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies. Proc. Natl. Acad. Sci. U.S.A. 102 12 (2005) 4240-4245
43. Townsley A., Senkevich T., and Moss B. Vaccinia virus A21 virion membrane protein is required for cell entry and fusion. J. Virol. 79 15 (2005) 9458-9469
44. Turner G., Squires E.J., and Murray H. Inactivated smallpox vaccine. A comparison of inactivation methods. J. Hyg. (Lond.) 68 2 (1970) 197-210
45. Vanhooren A., De Vriendt K., Devreese B., Chedad A., Sterling A., Van Dael H., Van Beeumen J., and Hanssens I. Selectivity of tryptophan residues in mediating photolysis of disulfide bridges in goat alpha-lactalbumin. Biochemistry 45 7 (2006) 2085-2093
46. Wolffe E.J., Vijaya S., and Moss B. A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 211 1 (1995) 53-63
47. Xiao Y., Aldaz-Carroll L., Ortiz A.M., Whitbeck J., Alexander E., Lou H., Davis H.L., Braciale T., Eisenberg R., Cohen G.H., and Isaacs S.N. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 25 7 (2007) 1214-1224